Form 4: Leslie V. Norwalk Reports Acquisition of Neurocrine Biosciences Stock and Options

Director Leslie V. Norwalk reported the acquisition of Neurocrine Biosciences Restricted Stock Units and Non-Qualified Stock Options on May 22, 2024.

Summary

• On May 22, 2024, Leslie V. Norwalk, a director of Neurocrine Biosciences Inc., acquired 1,435 Restricted Stock Units (RSUs) and 2,982 Non-Qualified Stock Options.
• The RSUs will vest in full on May 22, 2025.
• The options vest in 12 monthly installments beginning June 22, 2024.
• Following these transactions, Norwalk directly owns 1,435 RSUs and 2,982 Non-Qualified Stock Options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock and option grants to a director. While insider buying can be seen as a positive, this is part of a compensation package.

Positives

• The acquisition of stock and options by a director could be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. They are closely watched by investors for signals about management's view of the company's prospects.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of compensation for directors and executives in the biotechnology industry.
• The vesting schedules (one year for RSUs, monthly for options) are fairly standard.
• Comparing the size of the grant to those of directors at comparable companies (e.g., Biogen, Vertex) would provide further context.

Stakeholder Impact

• The acquisition of stock and options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates